Manufacturing Chemist

Breaking News

Oxford BioTherapeutics and Boehringer Ingelheim extend cancer immunology partnership

The two companies have extended their existing collaboration by a further two years, aiming to develop novel cancer immunotherapies

Catalent adds cryogenic capabilities to support gene development

The facility in Shiga will include the storage, kitting, and distribution of advanced therapies at ultra-low temperatures for clinical trials

Scarlet Therapeutics raises seed funding for rare disease treatment therapies

The platform also has the potential to treat other metabolic diseases requiring enzyme replacement therapy, as well as cancer and autoimmune diseases

Living in a material world

Mass consumption's rise has led to waste on a previously unimaginable scale. Kathy Illingworth, Head of Sustainability and Consulting at Ecoveritas...

20% of European biotechs headquartered in Switzerland

Evidence published in the Swiss Biotech Report reveals why Switzerland is now one of the most popular countries for European biotech companies

Arxada issues first sustainability report

The inaugural sustainability report reinforces the company’s commitment to building a sustainable future, highlights progress made to date and esta...

Accelerating drug discovery with market leading cell line generation

In January 2023, integrated drug discovery company Sygnature Discovery announced the acquisition of SB Drug Discovery, a world-leading provider of...

What to consider for successful GMP Annex 1 implementation

In advance of her presentation at Manufacturing Chemist Live, Dr Nicole Hunter (NH), Head of Global Regulatory and Validation Services at Watson-Ma...

Stablepharma publishes peer-reviewed article on world’s first fridge-free Tetanus diphtheria vaccine

Full recovery of vaccine potency, after 7–10 months at 45°C, was shown by complete protection against supra-lethal doses of active toxins

Touchlight creates giant London DNA manufacturing facility

Facility will have capacity that exceeds today’s global plasmid DNA demand and can enable commercialisation of genetic medicines

Network, learn and innovate at the heart of US pharma

Ahead of CPHI North America, Dr Kevin Robinson (KSR) spoke with Sarah Griffin (SG), Brand Manager at Informa, to get her perspectives on what’s new...

Highly potent formulation development in oncology

Formulation development is a dynamic and experimental process. However, certain challenges are presented to CDMOs that add a layer of unnecessary p...

AstraZeneca’s DELIVER Phase III trial reveals heart failure results

Presented at European Society of Cardiology’s Heart Failure 2023 congress, the trials supported the consistent benefits of Farxiga regardless of he...

New-generation silica nanoparticles: the next big thing in siRNA delivery systems for cancer treatment?

In this article, N4 Pharma's Nigel Theobold, CEO, and Dr David Templeton, Technical Director, consider how a novel silica nanoparticle could offer...

AlzeCure Pharma receives patent for anti-Alzheimer's drug

ACD856 and other substances in the NeuroRestore platform stimulate several important signalling systems and signalling molecules in the brain

Investigating DNA repair inhibitors to treat cancer and other inflammatory diseases

Many current chemotherapy drugs work by causing replication-associated DNA damage that kills individual cancer cells. However, as well as destroyin...